Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Unsuitability of lymphoblastoid cell lines as surrogate of cryopreserved isolated lymphocytes for the analysis of DNA double-strand break repair activity.

Zijno A, Porcedda P, Saini F, Allione A, Garofalo B, Marcon F, Guarrera S, Turinetto V, Minieri V, Funaro A, Crebelli R, Giachino C, Matullo G.

Mutat Res. 2010 Feb 3;684(1-2):98-105. doi: 10.1016/j.mrfmmm.2009.12.008. Epub 2009 Dec 24.

PMID:
20035771
2.

DNA repair phenotype and cancer susceptibility--a mini review.

Li C, Wang LE, Wei Q.

Int J Cancer. 2009 Mar 1;124(5):999-1007. doi: 10.1002/ijc.24126. Review.

3.

DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors.

Orlow I, Park BJ, Mujumdar U, Patel H, Siu-Lau P, Clas BA, Downey R, Flores R, Bains M, Rizk N, Dominguez G, Jani J, Berwick M, Begg CB, Kris MG, Rusch VW.

J Clin Oncol. 2008 Jul 20;26(21):3560-6. doi: 10.1200/JCO.2007.13.2654.

4.

No evidence for differences in DNA damage assessed before and after a cancer diagnosis.

Bhatti P, Sigurdson AJ, Thomas CB, Iwan A, Alexander BH, Kampa D, Bowen L, Doody MM, Jones IM.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):990-4. doi: 10.1158/1055-9965.EPI-07-2871.

5.

DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention.

Paz-Elizur T, Sevilya Z, Leitner-Dagan Y, Elinger D, Roisman LC, Livneh Z.

Cancer Lett. 2008 Jul 18;266(1):60-72. doi: 10.1016/j.canlet.2008.02.032. Epub 2008 Apr 18. Review.

6.

Mutagen sensitivity: a genetic predisposition factor for cancer.

Wu X, Gu J, Spitz MR.

Cancer Res. 2007 Apr 15;67(8):3493-5. Review.

7.

Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.

Chao DL, Maley CC, Wu X, Farrow DC, Galipeau PC, Sanchez CA, Paulson TG, Rabinovitch PS, Reid BJ, Spitz MR, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40.

8.

DNA damage among thyroid cancer and multiple cancer cases, controls, and long-lived individuals.

Sigurdson AJ, Hauptmann M, Alexander BH, Doody MM, Thomas CB, Struewing JP, Jones IM.

Mutat Res. 2005 Oct 3;586(2):173-88.

PMID:
16099702
9.

Methods for etiologic and early marker investigations in the PLCO trial.

Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, Reding D, Gelmann EP, Rothman N, Pfeiffer RM, Hoover RN, Berg CD; PLCO Trial Team.

Mutat Res. 2005 Dec 30;592(1-2):147-54. Epub 2005 Jul 27.

PMID:
16054167
10.

The use of EBV-transformed cell lines of breast cancer patients to measure chromosomal radiosensitivity.

Baeyens A, Thierens H, Vandenbulcke K, De Ridder L, Vral A.

Mutagenesis. 2004 Jul;19(4):285-90.

PMID:
15215327
11.

The molecular epidemiology of oxidative damage to DNA and cancer.

Caporaso N.

J Natl Cancer Inst. 2003 Sep 3;95(17):1263-5. No abstract available.

PMID:
12953074
12.

Genetic susceptibility to lung cancer: the role of DNA damage and repair.

Spitz MR, Wei Q, Dong Q, Amos CI, Wu X.

Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):689-98. Review. No abstract available.

13.
14.

Repair of oxidative DNA damage: assessing its contribution to cancer prevention.

Collins A, Harrington V.

Mutagenesis. 2002 Nov;17(6):489-93. Review.

PMID:
12435846
15.

Whole blood cryopreservation in epidemiological studies.

Hayes RB, Smith CO, Huang WY, Read Y, Kopp WC.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1496-8.

17.

Involvement of cell cycle control in bleomycin-induced mutagen sensitivity.

Cloos J, Temmink O, Ceelen M, Snel MH, Leemans CR, Braakhuis BJ.

Environ Mol Mutagen. 2002;40(2):79-84.

PMID:
12203399
18.
19.

Cryopreserving whole blood for functional assays using viable lymphocytes in molecular epidemiology studies.

Cheng L, Wang LE, Spitz MR, Wei Q.

Cancer Lett. 2001 May 26;166(2):155-63.

PMID:
11311488
20.

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.

Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S.

PMID:
11189683

Supplemental Content

Support Center